Literature DB >> 29344704

[The role of PSMA PET-CT in patients with metastatic prostate cancer].

J von Hardenberg1, K-A Büsing2, P Nuhn3, M Ritter3.   

Abstract

Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resistant prostate cancer evidence for its use is not available.

Entities:  

Keywords:  Castration-resistant prostate cancer (CRPC); Oligometastases; Primary diagnostic; Prostatectomy, radical; Recurrence

Mesh：

Substances：

Year:  2018        PMID： 29344704     DOI： 10.1007/s00117-018-0358-8

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


  38 in total

1.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

Authors:  Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.

Authors:  Wolfgang Peter Fendler; Jeremie Calais; Martin Allen-Auerbach; Christina Bluemel; Nina Eberhardt; Louise Emmett; Pawan Gupta; Markus Hartenbach; Thomas A Hope; Shozo Okamoto; Christian Helmut Pfob; Thorsten D Pöppel; Christoph Rischpler; Sarah Schwarzenböck; Vanessa Stebner; Marcus Unterrainer; Helle D Zacho; Tobias Maurer; Christian Gratzke; Alexander Crispin; Johannes Czernin; Ken Herrmann; Matthias Eiber
Journal:  J Nucl Med       Date:  2017-04-13       Impact factor: 10.057

3.  Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus 68Ga-DOTA NOC PET-CT.

Authors:  Sharjeel Usmani; Najeeb Ahmed; Fahad Marafi; Rashid Rasheed; Henney G Amanguno; Fareeda Al Kandari
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

4.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

Review 5.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.

Authors:  Jeffrey J Tosoian; Michael A Gorin; Ashley E Ross; Kenneth J Pienta; Phuoc T Tran; Edward M Schaeffer
Journal:  Nat Rev Urol       Date:  2016-10-11       Impact factor: 14.432

6.  Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.

Authors:  Neeta Pandit-Taskar; Darren R Veach; Josef J Fox; Howard I Scher; Michael J Morris; Steven M Larson
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

7.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.

Authors:  Sarah M Schwarzenböck; Matthias Eiber; Günther Kundt; Margitta Retz; Monique Sakretz; Jens Kurth; Uwe Treiber; Roman Nawroth; Ernst J Rummeny; Jürgen E Gschwend; Markus Schwaiger; Mark Thalgott; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-17       Impact factor: 9.236

Review 8.  Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.

Authors:  Maria L Lindenberg; Baris Turkbey; Esther Mena; Peter L Choyke
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

9.  Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer.

Authors:  C J D Wallis; P Cheung; S Herschorn; R Saskin; J Su; L H Klotz; G S Kulkarni; Y Lee; R T Kodama; S A Narod; R K Nam
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

10.  Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.

Authors:  Thomas P Shakespeare
Journal:  Radiat Oncol       Date:  2015-11-18       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.